Crinetics Pharmaceuticals (CRNX) Enterprise Value (2017 - 2025)
Crinetics Pharmaceuticals has reported Enterprise Value over the past 9 years, most recently at -$1.0 billion for Q4 2025.
- For Q4 2025, Enterprise Value rose 24.09% year-over-year to -$1.0 billion; the TTM value through Dec 2025 reached -$1.0 billion, up 24.09%, while the annual FY2025 figure was -$1.0 billion, 24.09% up from the prior year.
- Enterprise Value for Q4 2025 was -$1.0 billion at Crinetics Pharmaceuticals, up from -$1.1 billion in the prior quarter.
- Over five years, Enterprise Value peaked at -$34.6 million in Q4 2022 and troughed at -$1.4 billion in Q4 2024.
- A 5-year average of -$552.4 million and a median of -$351.3 million in 2021 define the central range for Enterprise Value.
- Biggest five-year swings in Enterprise Value: surged 89.63% in 2022 and later plummeted 2052.27% in 2024.
- Year by year, Enterprise Value stood at -$334.2 million in 2021, then surged by 89.63% to -$34.6 million in 2022, then crashed by 1512.41% to -$558.6 million in 2023, then crashed by 142.42% to -$1.4 billion in 2024, then grew by 24.09% to -$1.0 billion in 2025.
- Business Quant data shows Enterprise Value for CRNX at -$1.0 billion in Q4 2025, -$1.1 billion in Q3 2025, and -$1.2 billion in Q2 2025.